Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
317.50
+4.00 (1.28%)
Jul 7, 2026, 11:51 AM EDT - Market open
PRAX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
168
Market Cap
8.85B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 8.55M | 6.11M | 249.53% |
| Dec 31, 2023 | 2.45M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| Corcept Therapeutics | 769.10M |
| Mirum Pharmaceuticals | 569.61M |
| Rhythm Pharmaceuticals | 217.17M |
| ImmunityBio | 140.98M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
PRAX News
- 3 hours ago - Praxis Precision, Remagine Labs announce research collaboration and license pact - TheFly
- 4 hours ago - Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - GlobeNewsWire
- 4 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies - GlobeNewsWire
- 8 days ago - Praxis Precision price target raised to $575 from $510 at Needham - TheFly
- 15 days ago - Praxis Precision granted breakthrough therapy designation for elsunersen - TheFly
- 15 days ago - Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants - GlobeNewsWire
- 19 days ago - Praxis Precision initiated with an Outperform at RBC Capital - TheFly